This section highlights FDA-related milestones and regulatory updates for drugs developed by Beam Therapeutics (BEAM).
Over the past two years, Beam Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
risto-cel, BEAM-101, BEAM-302, and BEAM-103. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Risto-cel FDA Regulatory Events
Risto-cel is a drug developed by Beam Therapeutics for the following indication: sickle cell disease.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- risto-cel
- Announced Date:
- May 12, 2026
- Indication:
- sickle cell disease
Announcement
Beam Therapeutics Inc. announced that the company will present updated biomarker data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) at the European Hematology Association 2026 Congress (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden.
AI Summary
Beam Therapeutics said it will share updated biomarker data from the BEACON Phase 1/2 trial of ristoglogene autogetemcel, or risto-cel, at the European Hematology Association 2026 Congress in Stockholm from June 11-14, 2026. The update will highlight how the treatment may restore red blood cell health and function in people with sickle cell disease. The company said sickling and blood flow-related measures looked comparable to those seen in sickle cell trait, which suggests meaningful improvement in how the cells behave.
The data will be presented in a poster session on June 13 by Beam scientist Priya S. Chockalingam. Beam will also share a separate publication-only abstract on the link between fetal hemoglobin and clinical outcomes in sickle cell disease. Together, the presentations are expected to add to the evidence on how risto-cel may help address the underlying biology of the disease.
Read Announcement
BEAM-101 FDA Regulatory Timeline and Events
BEAM-101 is a drug developed by Beam Therapeutics for the following indication: Sickle cell diseas.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- BEAM-101
- Announced Date:
- April 1, 2026
- Indication:
- Sickle cell diseas
Announcement
Beam Therapeutics Inc announced the publication of data from the ongoing Phase 1/2 BEACON clinical trial evaluating ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) for the treatment of sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs) in The New England Journal of Medicine (NEJM).
AI Summary
Beam Therapeutics announced that data from the ongoing Phase 1/2 BEACON trial of ristoglogene autogetemcel (risto-cel, formerly BEAM-101) for sickle cell disease with severe vaso-occlusive crises was published in The New England Journal of Medicine on April 1, 2026. The paper, titled "Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease," reports clinical findings from 31 patients enrolled in the study.
Results showed deep resolution of red blood cell dysfunction and reduced time spent in hospital. Those benefits were achieved after a median of one cell collection cycle and were accompanied by rapid engraftment. The adult and adolescent cohorts were fully enrolled in mid-2025, and manufacturing of all doses was completed in December 2025. Beam expects to submit a U.S. biologics license application (BLA) for risto-cel as early as year-end 2026.
Read Announcement- Drug:
- BEAM-101
- Announced Date:
- December 6, 2025
- Indication:
- Sickle cell diseas
Announcement
Beam Therapeutics Inc. announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel), formerly known as BEAM-101, an investigational genetically modified ex vivo base editing cell therapy, in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).
AI Summary
Beam Therapeutics reported updated BEACON Phase 1/2 data for risto-cel in 31 adult and adolescent patients with severe sickle cell disease, with up to 20 months' follow-up. Patients showed mean fetal hemoglobin (HbF) above 60% and mean sickle hemoglobin (HbS) below 40%, durable through follow-up. Editing in blood averaged about 67% at month 6 and 73% by month 12. Hemoglobin rose and anemia resolved after transfused blood cleared, while markers of hemolysis and sickling improved to near sickle-trait levels. No investigator-reported severe vaso-occlusive crises occurred after engraftment.
Manufacturing was efficient: patients required a median of one stem cell collection cycle and three total collection days. Engraftment was rapid (median neutrophils 17.5 days, platelets 19 days) with a median seven days of severe neutropenia; 29% needed no platelet transfusion. The safety profile was consistent with busulfan conditioning and autologous HSCT, with common events like stomatitis and febrile neutropenia; one death was attributed to conditioning, not risto-cel.
Read Announcement- Drug:
- BEAM-101
- Announced Date:
- August 14, 2025
- Indication:
- Sickle cell diseas
Announcement
Beam Therapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).
AI Summary
Beam Therapeutics announced that the FDA granted RMAT designation to BEAM-101, an investigational gene-edited cell therapy for sickle cell disease (SCD). This one-time treatment uses patients’ own blood stem cells, precisely edited to boost fetal hemoglobin (HbF) levels and reduce sickle hemoglobin (HbS).
The RMAT status is designed to accelerate development and review of promising regenerative medicines for serious diseases. It gives Beam early access to FDA guidance on potential surrogate endpoints, priority and rolling review, and offers opportunities for meetings with senior agency staff and participation in novel development programs.
Beam has dosed 30 patients in its BEACON Phase 1/2 trial and expects more clinical data later this year. The therapy is manufactured through an advanced, largely automated process that achieves consistently high cell yields and viability. Beam remains focused on delivering a transformative one-time treatment to people living with severe SCD.
Read Announcement- Drug:
- BEAM-101
- Announced Date:
- June 13, 2025
- Indication:
- Sickle cell diseas
Announcement
Beam Therapeutics Inc. announces new safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).
AI Summary
Beam Therapeutics Inc. has announced encouraging new safety and efficacy data from its BEACON Phase 1/2 clinical trial for BEAM-101 in patients with sickle cell disease (SCD) experiencing severe vaso-occlusive crises (VOCs). In the updated analysis of 17 patients, all treated individuals showed a significant increase in fetal hemoglobin (HbF) above 60% and a reduction in sickle hemoglobin (HbS) below 40%, which is expected to help mimic the protective effects seen in sickle cell trait. Furthermore, patients experienced rapid engraftment of neutrophils and platelets, and required only a single mobilization cycle on median, contributing to the resolution of anemia and improved red blood cell health.
The findings reinforce BEAM-101’s potential to provide a transformative treatment for SCD by reducing hospitalizations and improving patient quality of life. The data builds on previous results and demonstrates a consistent safety profile aligned with busulfan conditioning and autologous stem cell transplantation, promising a new approach in the management of severe SCD symptoms.
Read Announcement- Drug:
- BEAM-101
- Announced Date:
- May 14, 2025
- Indication:
- Sickle cell diseas
Announcement
Beam Therapeutics Inc. announced that the company will present new data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the European Hematology Association 2025 Congress (EHA2025), taking place June 12-15, 2025, in Milan, Italy.
AI Summary
Beam Therapeutics Inc. announced that it will share updated safety and efficacy data from its ongoing BEACON Phase 1/2 clinical trial of BEAM-101, a one-time cell therapy for sickle cell disease (SCD), at the European Hematology Association 2025 Congress. The new data, derived from 17 SCD patients, highlights insights into BEAM-101’s potential to treat severe vaso-occlusive crises by increasing the production of fetal hemoglobin (HbF). The presentation, titled “Base Editing for Sickle Cell Disease: Ongoing Results from the BEACON Study Evaluating the Safety and Efficacy of BEAM-101,” is part of a series of sessions scheduled during the meeting, which will be held in Milan, Italy, from June 12-15, 2025. The company will also host an investor webcast on June 13, 2025, to discuss these key findings and their implications for precision genetic medicine in SCD.
Read Announcement- Drug:
- BEAM-101
- Announced Date:
- February 25, 2025
- Indication:
- Sickle cell diseas
Announcement
Beam Therapeutics Inc announced reiterated anticipated milestones across the company's hematology and genetic disease franchises.
AI Summary
Beam Therapeutics Inc has reiterated its anticipated milestones for its hematology and genetic disease franchises. The company achieved its adult enrollment target in the BEACON Phase 1/2 trial for BEAM-101, a genetically modified cell therapy for sickle cell disease, and has also enrolled its first adolescent patients. Beam expects to dose 30 patients in this trial and plan to present updated data by mid-2025. In addition to these hematology milestones, Beam is advancing its liver-targeted genetic disease programs. The company anticipates initial data from the Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency in the first half of 2025, and patient dosing for BEAM-301 in glycogen storage disease type 1a is expected to commence in early 2025. These milestones underline Beam’s commitment to developing precision genetic medicines and are supported by its strong financial position.
Read Announcement- Drug:
- BEAM-101
- Announced Date:
- January 23, 2025
- Indication:
- Sickle cell diseas
Announcement
Beam Therapeutics Inc. announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place February 12 – 15, 2025, in Honolulu, Hawaii.
AI Summary
Beam Therapeutics Inc. announced that it will present updated data from the BEACON Phase 1/2 clinical trial of its investigational gene editing therapy, BEAM-101, during an oral session at the 2025 Tandem Meetings. The event, organized by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), is scheduled for February 12–15, 2025, in Honolulu, Hawaii.
The BEACON trial, which focuses on treating sickle cell disease, includes data from patients receiving BEAM-101—a one-time therapy involving autologous CD34+ hematopoietic stem cells that are base-edited to boost fetal hemoglobin production. This approach has shown promising results with durable increases in fetal hemoglobin, reduced sickle hemoglobin, and rapid cell recovery, demonstrating a safety profile consistent with established treatment methods.
Read Announcement- Drug:
- BEAM-101
- Announced Date:
- December 7, 2024
- Indication:
- Sickle cell diseas
Announcement
Beam Therapeutics Inc. announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).
AI Summary
Beam Therapeutics Inc. announced promising new results from its BEACON Phase 1/2 clinical trial of BEAM-101, a base-editing treatment for patients with severe sickle cell disease experiencing frequent vaso-occlusive crises. The data, presented at the ASH Annual Meeting in San Diego, showed that all seven treated patients achieved over 60% fetal hemoglobin levels while reducing sickle hemoglobin below 40%, effectively resolving anemia. In addition, patients experienced rapid neutrophil and platelet engraftment and marked improvements or normalization of hemolysis markers. These early findings demonstrate BEAM-101’s potential to significantly improve the hemoglobin profile, offering a differentiated, durable treatment option for those with severe sickle cell disease. The innovative approach combines autologous hematopoietic stem cell transplantation with advanced base editing, aiming to reduce the risks and complications typically associated with traditional transplant conditioning.
Read Announcement- Drug:
- BEAM-101
- Announced Date:
- June 14, 2024
- Indication:
- Sickle cell diseas
Announcement
Beam Therapeutics Inc. reported data highlighting its optimized, closed and automated manufacturing process for its base-edited CD34+ hematopoietic stem and progenitor cell (HSPC) genetic medicines in a poster presentation at the European Hematology Association (EHA) Hybrid Congress.
AI Summary
Beam Therapeutics recently presented data at the European Hematology Association (EHA) Hybrid Congress that showcases its advanced manufacturing process for base-edited CD34+ hematopoietic stem and progenitor cell (HSPC) genetic medicines. The process is both closed and automated, leading to robust product yields and high cell viability. Automation has helped increase cumulative yield, process consistency, and production capacity while reducing the risk of contamination and operator variability.
This optimized process is being used to manufacture BEAM-101, a product in Beam’s BEACON Phase 1/2 clinical trial for patients with severe sickle cell disease. The data showed consistently high CD34+ purity and editing rates, which are crucial for ensuring the quality of the genetic medicine. Overall, the improvements in Beam’s manufacturing methods add value by enhancing the reproducibility and efficiency of the production process for this precision therapy.
Read Announcement
BEAM-302 FDA Regulatory Timeline and Events
BEAM-302 is a drug developed by Beam Therapeutics for the following indication: In Alpha-1 Antitrypsin Deficiency (AATD).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- BEAM-302
- Announced Date:
- March 25, 2026
- Indication:
- In Alpha-1 Antitrypsin Deficiency (AATD)
Announcement
Beam Therapeutics announced updated safety and efficacy data from the ongoing Phase 1/2 trial of BEAM-302 and the selection of 60 mg as the optimal biological dose to advance into pivotal development to support potential accelerated approval.
AI Summary
Beam Therapeutics reported updated Phase 1/2 results for BEAM-302 showing strong and durable biological activity at a 60 mg dose. Mean steady-state total AAT reached 16.1 µM, and all patients stayed above the 11 µM protective AAT threshold for up to 12 months. Corrected M‑AAT made up 94% of total AAT and mutant Z‑AAT was reduced by 84% after 60 mg treatment. Infections post‑treatment showed the liver could still boost AAT: one patient rose to ~30 µM total AAT with 95% M‑AAT. These data come from 28 efficacy‑evaluable patients and indicate rapid, lasting increases in functional AAT and new production of corrected protein.
Safety was favorable, with single doses up to 75 mg well tolerated and consistent across Part A and Part B cohorts. Based on the safety and efficacy profile, Beam selected 60 mg as the optimal biological dose to advance into pivotal development to support potential accelerated approval. A global pivotal cohort is expected to start in the second half of 2026. Beam will host an investor webcast today, March 25, 2026, at 8:00 a.m. ET.
Read Announcement- Drug:
- BEAM-302
- Announced Date:
- January 11, 2026
- Indication:
- In Alpha-1 Antitrypsin Deficiency (AATD)
Announcement
Beam Therapeutics Inc. nnounced continued progress toward its mission to build a sustainable, predictable model for the advancement of precision genetic medicines, highlighting recent updates for its liver-targeted genetic disease and hematology franchises and strategic priorities in 2026, supported by an extended anticipated operating runway.
AI Summary
Beam Therapeutics said it is making steady progress toward a predictable, sustainable model for precision genetic medicines, highlighting updates across its liver-targeted genetic disease and hematology franchises and strategic priorities for 2026. In the liver franchise, BEAM-302 showed the first clinical in vivo correction of a disease-causing mutation in alpha-1 antitrypsin deficiency and has treated more than 25 patients in dose exploration. The company plans an expansion of the Phase 1/2 study with roughly 50 additional patients and expects updated data and next steps for pivotal development by the end of Q1 2026. BEAM-301 for GSDIa is advancing through dose cohorts, with initial clinical data expected in 2026 and a new liver program to be announced in H1 2026.
In hematology, risto-cel (formerly BEAM-101) showed differentiated clinical signals in sickle cell disease, with the BEACON trial fully enrolled and manufacturing completed in December 2025. Beam anticipates a BLA submission as early as year-end 2026 while advancing next-generation in vivo and ESCAPE programs. The company reported about $1.25 billion in cash and expects an operating runway into 2029 to support its 2026 plans and key program execution.
Read Announcement- Drug:
- BEAM-302
- Announced Date:
- May 29, 2025
- Indication:
- In Alpha-1 Antitrypsin Deficiency (AATD)
Announcement
Beam Therapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD).
AI Summary
Beam Therapeutics Inc has earned orphan drug designation from the FDA for BEAM-302, an innovative treatment designed for patients with alpha-1 antitrypsin deficiency (AATD). BEAM-302 is a liver-targeting lipid nanoparticle (LNP) that delivers both a guide RNA and an mRNA encoding a base editor, aiming to fix the disease-causing mutation at its source. This designation recognizes BEAM-302 as a promising therapy for a rare condition that causes early lung damage and liver disease. It also offers important benefits to Beam Therapeutics, such as tax credits and market exclusivity, to help support its further development. The FDA’s recognition underscores the critical need for new treatments for AATD and highlights BEAM-302’s potential to offer a one-time, possibly curative option for patients suffering from this serious genetic disorder.
Read Announcement- Drug:
- BEAM-302
- Announced Date:
- May 12, 2025
- Indication:
- In Alpha-1 Antitrypsin Deficiency (AATD)
Announcement
Beam Therapeutics Inc announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD).
AI Summary
Beam Therapeutics Inc. announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its innovative treatment BEAM-302. This product is a liver-targeting lipid-nanoparticle that carries a guide RNA and an mRNA encoding a base editor designed to correct the mutation responsible for alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting lung and liver function.
Receiving RMAT designation recognizes the treatment’s potential as a transformative, one-time therapy for AATD patients. This status enables Beam Therapeutics to work closely with the FDA, allowing early discussions on clinical endpoints and potentially faster regulatory review. The designation underscores promising clinical data and the hope that BEAM-302 could offer an effective and lasting solution to counter the effects of this serious condition.
Read Announcement- Drug:
- BEAM-302
- Announced Date:
- April 5, 2025
- Indication:
- In Alpha-1 Antitrypsin Deficiency (AATD)
Announcement
Beam Therapeutics Inc. presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress, taking place April 4-5, 2025, in Lisbon, Portugal.
AI Summary
Beam Therapeutics Inc. presented new data from the Phase 1/2 clinical trial of BEAM-302 for patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress in Lisbon, Portugal, held on April 4-5, 2025. The updated results from the 60 mg dose cohort showed a mean of 91% corrected M-AAT out of total AAT in circulation by Day 28. Additionally, the trial observed a 79% decrease in the mutant Z-AAT protein levels from baseline at the same time point. Beam’s data suggest that a single dose of BEAM-302 can achieve rapid, dose-dependent correction of the disease-causing mutation, offering potential therapeutic benefits for patients with AATD. The company is also enrolling a 75 mg dose cohort and plans to present further data later in 2025.
Read Announcement- Drug:
- BEAM-302
- Announced Date:
- March 27, 2025
- Indication:
- In Alpha-1 Antitrypsin Deficiency (AATD)
Announcement
Beam Therapeutics announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD).
AI Summary
Beam Therapeutics has received FDA clearance for its investigational new drug (IND) application for BEAM-302, a potential treatment for alpha-1 antitrypsin deficiency (AATD). This clearance marks an important step for the company’s program in the United States. BEAM-302 is a liver-targeting lipid-nanoparticle formulation that delivers a guide RNA and mRNA encoding a base editor designed to correct the disease-causing PiZ mutation in patients with AATD. The treatment aims to address both lung and liver complications by correcting the genetic mutation responsible for the condition. Beam Therapeutics is currently evaluating the safety, tolerability, and effectiveness of BEAM-302 in an ongoing Phase 1/2, open-label clinical trial. With this regulatory clearance, the company is set to expand patient enrollment and further explore this innovative approach that holds the promise of a one-time, curative treatment for AATD in the U.S.
Read Announcement- Drug:
- BEAM-302
- Announced Date:
- March 10, 2025
- Indication:
- In Alpha-1 Antitrypsin Deficiency (AATD)
Announcement
Beam Therapeutics announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing. Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was well tolerated, with single doses of BEAM-302 leading to durable dose-dependent correction of the disease-causing mutation.
AI Summary
Beam Therapeutics announced early safety and efficacy findings from its Phase 1/2 trial of BEAM-302, a therapy aimed at treating alpha-1 antitrypsin deficiency (AATD) through in vivo base editing. The trial’s initial results show that single doses of BEAM-302 were well tolerated across three ascending dose levels, with no serious adverse events. Notably, the highest dose achieved a mean total AAT level that exceeded the protective therapeutic threshold by Day 28. The data demonstrated a durable, dose-dependent correction of the disease-causing mutation, leading to increased levels of total and functional AAT and a significant reduction (up to 78%) in the harmful mutant Z-AAT protein. These promising results confirm the clinical proof-of-concept for BEAM-302 as a potential one-time treatment for AATD and highlight its innovative use of base editing to address genetic disorders at the DNA level.
Read Announcement- Drug:
- BEAM-302
- Announced Date:
- June 26, 2024
- Indication:
- In Alpha-1 Antitrypsin Deficiency (AATD)
Announcement
Beam Therapeutics Inc. announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe alpha-1 antitrypsin deficiency (AATD), that is currently being evaluated in a Phase 1/2 clinical trial.
AI Summary
Beam Therapeutics Inc. announced an important milestone in its fight against severe alpha-1 antitrypsin deficiency (AATD). The company treated its first patient with BEAM-302, an investigational in vivo base editing medicine designed to correct the genetic mutation that causes AATD. This new treatment directly targets the PiZ mutation responsible for the production of misfolded AAT protein, which can damage the liver and lead to lung problems.
The BEAM-302 treatment uses a liver-targeting lipid nanoparticle to deliver base editing reagents, aiming to restore the gene to its normal function. Beam Therapeutics is currently evaluating this approach in a Phase 1/2 clinical trial to assess safety, dosage, and early signs of effectiveness. The company hopes this one-time treatment can provide a more precise and lasting solution compared to conventional therapies, ultimately offering new hope to patients suffering from both lung and liver complications related to AATD.
Read Announcement
BEAM-103 FDA Regulatory Events
BEAM-103 is a drug developed by Beam Therapeutics for the following indication: Treating Sickle Cell Disease.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- BEAM-103
- Announced Date:
- December 8, 2024
- Indication:
- Treating Sickle Cell Disease
Announcement
Beam Therapeutics Inc. announced new data for its Engineered Stem Cell Antibody Evasion (ESCAPE) conditioning platform.
AI Summary
Beam Therapeutics Inc. recently unveiled encouraging data for its Engineered Stem Cell Antibody Evasion (ESCAPE) conditioning platform at the 66th American Society of Hematology Annual Meeting. In a non-human primate study, researchers used an anti-CD117 monoclonal antibody (BEAM-103) to condition the animals. This approach enabled long-term engraftment of base-edited hematopoietic stem cells while inducing sustained and robust levels of fetal hemoglobin (HbF). The study showed that the antibody conditioning allowed for the near complete replacement of wild-type erythroid cells by edited cells, with edited cells present in circulation for over six months and HbF levels reaching above 80%. These promising findings suggest that ESCAPE may offer a safer, non-genotoxic alternative to traditional conditioning regimens, potentially paving the way for more accessible gene editing therapies for diseases such as sickle cell disease and beta-thalassemia.
Read Announcement
